Video
Prospects for Improving Cognitive Impairment in Early MS With Ozanimod: Robert Zivadinov, MD, PhD
Author(s):
The director of the Buffalo Neuroimaging Analysis Center talked about the ENLIGHTEN trial, where results showed a correlation between cognitive impairment and brain volume with ozanimod. [WATCH TIME: 5 minutes]
WATCH TIME: 5 minutes
"While there was numerically a very good correlation [between cognitive impairment and brain volume], it did not reach significance; however, it was probably because the disease duration was very narrow in this study, but it was all in the right direction. We hope that over the next three studies, which will be the three years of follow up, we are going to see meaningful results.”
Ozanimod (Zeposia; BMS), an FDA-approved sphingosine 1-phosphate (S1P) receptor modulator for multiple sclerosis (MS), is a selective agent that offers easier use for patients with comorbidities. The therapy is currently being investigated in a multicenter, longitudinal, single-arm, open-label study called ENLIGHTEN (NCT04140305), which explores the change from baseline in cognitive processing speed in patients with relapsing-remitting MS treated with doses of 1 mg over 3 years.
Recently, Robert Zivadinov, MD, PhD, spoke in a platform session focused on imaging at the 2023 Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, held May 31 to June 3, in Aurora, Colorado. In his presentation titled “Relationship Between Baseline Cognitive Performance and Brain Volume Outcomes in Patients with Relapsing Multiple Sclerosis in ENLIGHTEN: Phase 3b Study of Ozanimod,” he discussed the critical imaging findings from the study.1
At the meeting, Zivadinov sat down in an interview with NeurologyLive® to provide an overview of his presentation on the results, and specifically, the criteria that was used for patient enrollment in the study. He also spoke about how the study assessed the correlation between cognitive impairment and brain volume. In addition, Zivadinov explained the potential prospects for improving cognitive outcomes in patients with early MS using ozanimod as a therapy based on the initial findings of the study.
Click here for more coverage of CMSC 2023.
